1. Universidade Federal da Bahia
  2. Instituto de Ciências da Saúde (ICS)
  3. Programa de Pós-Graduação em Processos Interativos dos Órgãos e Sistemas (PPGPIOS)
  4. Tese (PPGPIOS)
Please use this identifier to cite or link to this item: https://repositorio.ufba.br/handle/ri/38873
Full metadata record
DC FieldValueLanguage
dc.creatorRocha, Flávia Godinho Costa Wanderley-
dc.date.accessioned2024-01-15T13:50:45Z-
dc.date.available2024-01-15T13:50:45Z-
dc.date.issued2023-12-13-
dc.identifier.citationROCHA, Flávia Godinho Costa Wanderley. Medicamentos antirreabsortivos: perfil técnico científico dos cirurgiões-dentistas. 112 f. 2023. Tese (Doutorado) - Universidade Federal da Bahia, Instituto de Ciências da Saúde, Programa de Pós-Graduação em Processos Interativos dos Órgãos e Sistemas, Salvador, 2023.pt_BR
dc.identifier.urihttps://repositorio.ufba.br/handle/ri/38873-
dc.description.abstractIntroduction - Antiresorptive drugs are medications frequently used in the treatment of bone disorders and metastatic malignancies. However, chronic use of these medications can result in osteonecrosis of the jaws. Among the drugs of the antiresorptive class, bisphosphonates and denosumabs have stood out. Objective - To determine the level of scientific information of dental surgeons who carry out their professional activities in the state of Bahia (Brazil) about antiresorptive drugs and indicated pharmacological procedures aiming at the prevention of osteonecrosis of the jaws and the therapy of drug sequelae that may occur, considering the time since graduation in Dentistry and the academic qualification of these professionals. Methodology - This is a quantitative cross-sectional study in which 339 dentists were consulted using the virtual questionnaire containing topics of personal nature and professional, elements contained in the anamnesis carried out and knowledge about antiresorptive drugs, including indications, adverse effects and treatments applied. Chi-square and Fisher's exact tests were performed to analyze associations of data described by absolute and relative frequencies with professionals' time since graduation. All analyses were performed using the R software, with 5% significance level. Results - Among the 339 survey participants, the majority were female (76.4%), aged 31-35 years (25.1%). Furthermore, a large part of the professionals had a degree in dentistry obtained in the University category (49.0%), in the state of Bahia (80.5%). In relation to variables related to professional performance, those ones who revealed to have graduated for more than five years with the highest academic degree were those who demonstrated maximum knowledge of antiresorptive drugs or revealed that somehow, they had information about them (p<0,05). Conclusion - Dental surgeons in Brazil who have more than five years since graduation have more scientific information about antiresorptive drugs and pharmacological procedures, which can positively contribute to the prevention of osteonecrosis of the jaws and treatment of drug sequelae that may occur. Additionally, this current work highlights the need to highlight more in undergraduate dentistry courses the issues relating to antiresorptive drugs, as professionals with skills are needed to avoid and or interrupt the serious sequelae that may occur in the jaws of individuals who use these medications.pt_BR
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado da Bahia (FAPESB)pt_BR
dc.languageporpt_BR
dc.publisherUniversidade Federal da Bahiapt_BR
dc.subjectConhecimentopt_BR
dc.subjectOdontólogospt_BR
dc.subjectBisfosfonatospt_BR
dc.subjectDifosfonatospt_BR
dc.subjectMedicamentos antirreabsortivospt_BR
dc.subjectConservadores da densidade ósseapt_BR
dc.subjectOsteonecrosept_BR
dc.subject.otherKnowledgept_BR
dc.subject.otherDentistspt_BR
dc.subject.otherBisphosphonatespt_BR
dc.subject.otherDiphosphonatespt_BR
dc.subject.otherAntiresorptive drugspt_BR
dc.subject.otherBone Density Conservation Agentspt_BR
dc.subject.otherOsteonecrosispt_BR
dc.titleMedicamentos antirreabsortivos: perfil técnico-científico dos cirurgiões-dentistaspt_BR
dc.typeTesept_BR
dc.contributor.refereesAraújo, Roberto Paulo Correia de-
dc.publisher.programPrograma de Pós-Graduação em Processos Interativos dos Órgãos e Sistemas (PPGORGSISTEM) pt_BR
dc.publisher.initialsUFBApt_BR
dc.publisher.countryBrasilpt_BR
dc.subject.cnpqCNPQ::CIENCIAS BIOLOGICASpt_BR
dc.subject.cnpqCNPQ::CIENCIAS DA SAÚDEpt_BR
dc.contributor.advisor1Araújo, Roberto Paulo Correia de-
dc.contributor.advisor1Latteshttp://lattes.cnpq.br/8389914651900629pt_BR
dc.contributor.referee1Silva, Daniela Nascimento-
dc.contributor.referee1Latteshttp://lattes.cnpq.br/3613001852759565pt_BR
dc.contributor.referee2Mello, Sandra Maria Ferraz-
dc.contributor.referee2Latteshttp://lattes.cnpq.br/4661074667104305pt_BR
dc.contributor.referee3Fernandes, Atson Carlos de Souza-
dc.contributor.referee3Latteshttp://lattes.cnpq.br/8458546406023605pt_BR
dc.contributor.referee4Araújo, Danilo Barral de-
dc.contributor.referee4Latteshttp://lattes.cnpq.br/1197511486365047pt_BR
dc.contributor.referee5Aguiar, Márcio Cajazeira-
dc.contributor.referee5Latteshttp://lattes.cnpq.br/5406678886333526pt_BR
dc.creator.Latteshttp://lattes.cnpq.br/5254842464226381pt_BR
dc.description.resumoIntrodução – Os fármacos antirreabsortivos são medicações frequentemente utilizadas no tratamento de desordens ósseas e de neoplasias malignas metastásicas. No entanto, o uso crônico desses medicamentos pode resultar em osteonecrose dos maxilares. Dentre esses medicamentos da classe antirreabsortiva, têm se destacado os bisfosfonatos e os denosumabes. Objetivo – Verificar o nível de informações técnico-científicas dos cirurgiões-dentistas que exercem suas atividades profissionais no estado da Bahia (Brasil) sobre medicamentos antirreabsortivos e procedimentos farmacológicos indicados visando à prevenção da osteonecrose dos maxilares e o tratamento das sequelas medicamentosas que possam ocorrer, considerando o tempo de formado em Odontologia e a titulação acadêmica destes profissionais. Metodologia – Trata-se de um estudo transversal quantitativo. Nele, foram consultados 339 dentistas por meio de um questionário virtual com tópicos de caráter pessoal e profissional, elementos contidos na anamnese realizada e o conhecimento acerca dos fármacos antirreabsortivos, incluindo indicações, efeitos adversos e tratamentos empregados. Foram realizados os testes de qui-quadrado e exato de Fisher para analisar as associações dos dados descritos por frequências absoluta e relativa com o tempo de formado dos profissionais. Todas as análises foram feitas no programa R, com nível de significância de 5%. Resultados – Entre os 339 participantes da pesquisa, a maioria era do sexo feminino (76,4%), com faixa etária de 31-35 anos (25,1%). Ademais, uma grande parte dos profissionais tinha graduação em odontologia obtida na categoria Universidade (49,0%), no estado da Bahia (80,5%). Em relação às variáveis relacionadas ao desempenho profissional, aqueles que possuíam maior titulação, foram os que demonstraram conhecimento máximo dos fármacos antirreabsortivos ou revelaram que, de alguma forma, tinham informações sobre os mesmos (p<0,05). Conclusão – Os cirurgiões-dentistas do Brasil que têm mais de cinco anos de graduação e maior titulação acadêmica possuem mais informações científicas sobre os medicamentos antirreabsortivos e procedimentos farmacológicos, o que pode contribuir positivamente para a prevenção da osteonecrose dos maxilares e o tratamento das sequelas medicamentosas que possam ocorrer. Adicionalmente, este atual trabalho alerta para a necessidade de evidenciar mais nos cursos de graduação em odontologia os assuntos referentes aos fármacos antirreabsortivos, pois se necessita de profissionais com competências para evitar e ou interromper as graves sequelas que possam ocorrer nos maxilares dos indivíduos que utilizam esses medicamentos.pt_BR
dc.publisher.departmentInstituto de Ciências da Saúde - ICSpt_BR
dc.relation.references1. Reid IR, Billington EO. Drug therapy for osteoporosis in older adults. Lancet. 2022;399(10329):1080-92. doi: 10.1016/S0140-6736(21)02646-5 2. Inoue D. [Regulation of bone remodeling by anti-resorptives.]. Clin Calcium. 2017;27(12):1775-83. 3. Allen MR. Recent Advances in Understanding Bisphosphonate Effects on Bone Mechanical Properties. Curr Osteoporos Rep. 2018;16(2):198-204. doi: 10.1007/ s11914-018-0430-3 4. Dell'aquila E, Armento G, Iuliani M, Simonetti S, D'Onofrio L, Zeppola T, et al. Denosumab for cancer-related bone loss. Expert Opin Biol Ther. 2020; 20(11):126174. doi: 10.1080/14712598.2020.1814731 5. Teixeira S, Branco L, Fernandes MH, Costa-Rodrigues J. Bisphosphonates and Cancer: A relationship beyond the antiresorptive effects. Mini Ver Med Chem. 2019; 9(12):98898. doi: 10.2174/1389557519666190424163044 6. Kettenberger U, Luginbuehl V, Procter P, Pioletti DP. In vitro and in vivo investigation of bisphosphonate-loaded hydroxyapatite particles for peri-implant bone augmentation. J TissueEng Regen Med. 2017;11(7):1974-85. doi: 10.1000/term.2094 7. Chapurlat R, Legrand MA. Bisphosphonates for the treatment of fibrous dysplasia of bone. Bone. 2021;143:115784. doi: 10.1016/j.bone2020.115784 8. Kawamura H, Watanabe S, Takashi I, Asahina I, Moriuchi H, Dateki S. Efficacy and safety of denosumab treatment in a prepubertal patient with cherubism. J Pediatr Endocrinol Metab. 2020;33(7):963-6. doi: 10.1515/jpem-2019-0581 9. Kuźnik A, Październiok-Holewa A, Jewula P, Kuźnik N. Bisphosphonates-much more than only drugs for bone diseases. Eur J Pharmacol. 2020;866:172773. doi: 10.1016/j.ejphar.2019.17277 10. Xing L, Ebetino FH, Boeckman RK Junior, Srinivasan V, Tao J, Sawyer TK, et al. Targeting anti-cancer agents to bone using bisphosphonates. Bone. 2020; 138:115492. doi: 10.1016/j.bone.2020.115492 11. Querrer R, Ferrare N, Melo N, Stefani CM, Dos Reis PED, Mesquita CRM, et al. Differences between bisphosphonate-related and denosumab-related osteonecrosis of the jaws: a systematic review. Support Care Cancer. 2021;29(6):2811-20. doi: 10.1007/s00520-020-05855-6 12. Aldhalaan NA, Baqais A, Al-omar A. Medication-related osteonecrosis of the jaw: a review. Cureus. 2020;12(2):6944. doi: 10.7759/cureus.6944 13. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American association of oral and maxillofacial surgeons position paper on medicationrelated osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg. 2014;72(10):193856. doi: 10.1016/j.joms.2014.04.031 71 14. Campisi G, Mauceri R, Bertoldo F, Bettini G, Biasotto M, Colella G, et al. MedicationRelated Osteonecrosis of Jaws (MRONJ) Prevention and Diagnosis: Italian Consensus Update 2020. Int J Environ Res Public Health. 2020;17(16):5998. doi: 10.3390/ijerph17165998 15. Maciel AP, Quispe RA, Martins LJO, Caldas RJ, Santos PSDS. Clinical profile of individuals with bisphosphonate-related osteonecrosis of the jaw: an integrative review. São Paulo Med J. 2020; 138(4):326-35. doi:10.1590/1516 -3180.2019.0352.r2.15052020 16. Ribeiro GH, Chrun ES, Dutra KL, Daniel FI, Grando LJ. Osteonecrosis of the jaws: a review and update in etiology and treatment. Braz J Otorhinolaryngol. 2017;84(1):102-8. doi: 10.1016/j.bjorl.2017.05.008 17. Mauceri R, Coniglio R, Abbinante A, Carcieri P, Tomassi D, Panzarella V, et al. The preventive care of medication-related osteonecrosis of the jaw (MRONJ): a position paper by Italian experts for dental hygienists. Support Care Cancer. 2022;30(8):6429-40. doi: 10.1007/s00520-022-06940-8 18. Kim JM, Lin C, Stavre Z, Greenblatt MB, Shim JH. Osteoblast-Osteoclast Communication and Bone Homeostasis. Cells. 2020;9(9):2073. doi:10.3390/ cells9092073 19. Giudice A, Antonelli A, Chiarella E, Baudi F, Barni T, Di Vito A. The case of medication-related osteonecrosis of the jaw addressed from a pathogenic point of view. innovative therapeutic strategies: focus on the most recent discoveries on oral mesenchymal stem cell-derived exosomes. Pharmaceuticals. 2020;13(12):423. doi: 10.3390/ph13120423 20. Voss PJ, Steybe D, Poxleitner P, Schmelzeisen R, Munzenmayer C, Fuellgraf H, et al. Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis. Odontology. 2018;106(4);469-80. doi: 10.1007/s10266-0180362-5 21. Neville WB, Damm DD, Allen CM, Bouquot JE. Patologia oral & maxilofacial. 3. ed. Rio de Janeiro: Guanabara Koogan; 2009. 22. Vallina C, Ramírez L, Torres J, Casañas E, Hernández G, López-Pintor RM. Osteonecrosis of the jaws produced by sunitinib: a systematic review. Med Oral Patol Oral Cir Bucal. 2019;(24(3):e326-e338. doi:10.4317/medoral. 22858 23. Garuti F, Camelli V, Spinardi L, Bucci L, Trevisani F. Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma. Tumori. 2016; 102(Suppl.2). doi: 10.5301/tj.5000504. 24. Maluf G, Caldas RJ, Fregnani ER, da Silva Santos PS. A rare case of bevacizumabrelated osteonecrosis of the jaw associated with dental implants. Int J Implant Dent. 2019; 5(1):34. doi: 10.1186/s40729-019-0188- 72 25. Hasegawa T, Kawakita A, Ueda N, Funahara R, Tachibana A, Kobayashi M, et al. A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ? Osteoporos Int. 2017;28(8):2465-73. doi: 10.1007/s00198-017-4063-7 26. Wick A, Bankosegger P, Otto S, Hohlweg-Majert B, Steiner T, Probst F, et al. Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab. Clin Oral Investig. 2022;26(3):2839-52. doi: 10.1007/s00784021-04261-4 27. Nicolatou-Galitis O, Schiødt M, Mendes RA, Ripamonti C, Hope S, Drudge-Coates L, et al. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019;127(2):11735. doi: 10.1016/j.oooo.2018.09. 008 28. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22(10):147991. doi: 10.1359/jbmr.0707onj 29. Bermúdez-Bejarano EB, Serrera-Figallo MÁ, Gutiérrez-Corrales A, Romero-Ruiz MM, Castillo-de-Oyagüe R, Gutiérrez-Pérez JL, et al. Analysis of different therapeutic protocols for osteonecrosis of the jaw associated with oral and intravenous bisphosphonates. Med Oral Patol Oral Cir Bucal. 2017;22(1):e43-e57. doi: 10.4317/medoral.21477 30. Endo Y, Kumamoto H, Nakamura M, Sugawara S, Takano-Yamamoto T, Sasaki K, et al. Underlying Mechanisms and Therapeutic Strategies for BisphosphonateRelated Osteonecrosis of the Jaw (BRONJ). Biol Pharm Bull. 2017; 40(6):739-50. doi: 10.1248/bpb.b16-01020 31. Jung J, Park JS, Righesso L, Pabst AM, Al-Nawas B, Kwon YD, et al. Effects of an oral bisphosphonate and three intravenous bisphosphonates on several cell types in vitro. Clin Oral Investig. 2018;22(7):2527-34. doi: 10.1007/s00784-018-2349-6 32. Koyama C, Hirota M, Okamoto Y, Iwai T, Ogawa T, Hayakawa T, et al. A nitrogencontaining bisphosphonate inhibits osteoblast attachment and impairs bone healing in bone-compatible scaffold. J Mech Behav Biomed Mater. 2020; 104:103635. doi: 10.1016/j.jmbbm.2020.103635 33. Khan AA, Morrison A, Kendler DL, Rizzoli R, Hanley DA, Felsenberg D, et al. Casebased review of osteonecrosis of the jaw (onj) and application of the international recommendations for management from the international task force on ONJ. J Clin Densitom. 2017;20(1):8-24. doi:10.1016/j. jocd.2016.09.005 34. Eguia A, Bagán-debón L, Cardona F. Review and update on drugs related to the development of osteonecrosis of the jaw. Med Oral Patol Oral Cir Bucal. 2020; 25(1):e71e83. doi: 10.4317/medoral.23191 73 35. Cremers S, Drake MT, Ebetino FH, Bilezikian JP, Russell RGG. Pharmacology of bisphosphonates. Br J Clin Pharmacol. 2019;85(6):1052-62. doi:10.1111/bcp. 13867 36. Zhang N, Zhang ZK, Yu Y, Zhuo Z, Zhang G, Zhang BT. Pros and cons of denosumab treatment for osteoporosis and implication for rankl aptamer therapy. Front Cell Dev Biol. 2020;8:325. doi: 10.3389/fcell.2020.00325 37. Farrier AJ, Sanchez Franco LC, Shoaib A, Gulati V, Johnson N, Uzoigwe CE, et al. New anti-resorptives and antibody mediated anti-resorptive therapy. Bone Joint J. 2016; 98B(2):160-5. doi: 10.1302/0301-620X.98B2.36161 38. Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, et al. A single‐dose placebo‐ controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2004;19(7):1059-66. doi: 10.1359/JBMR.040305 39. Anastasilakis AD, Makras P, Yavropoulou MP, Tabacco G, Naciu AM, Palermo A. Denosumab discontinuation and the rebound phenomenon: a narrative review. J Clin Med. 2021;10(1):152. doi: 10.3390/jcm10010152 40. Tofé VI, Bagán L, Bagán JV. Osteonecrosis of the jaws associated with denosumab: Study of clinical and radiographic characteristics in a series of clinical cases. J Clin Exp Dent. 2020;12(7):e676-81. doi: 10.4317/jced.57019 41. Salgueiro M, Stribos M, Zhang LF, Stevens M, Awad ME, Elsalanty M. Value of preoperative CTX serum levels in the prediction of medication-related osteonecrosis of the jaw (MRONJ): a retrospective clinical study. EPMA J. 2019;10(1):21-9. doi: 10.1007/s13167-019-0160-3 42. Kuo TR, Chen CH. Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives. Biomark Res. 2017;5:18. doi: 10.1186/s40364-0170097-4 43. Song M. Dental care for patients taking antiresorptive drugs: a literature review. Restor Dent Endod. 2019;44(4):e42. doi: 10.5395/rde.2019.44.e42 44. Kim HY. Review and update of the risk factors and prevention of antiresorptive-related osteonecrosis of the jaw. Endocrinol Metab (Seoul). 2021; 36(5):917-27. doi: 10.3803/EnM.2021.1170 45. Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.Ann Oncol. 2009;20(1):117-20. doi: 10.1093/annonc/mdn554 74 46. Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, et al. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37(25):2270-90. doi:10.1200/ JCO.19.01186 47. Ribeiro GH, Chrun ES, Dutra KL, Daniel FI, Grando LJ. Osteonecrosis of the jaws: a review and update in etiology and treatment. Braz J Otorhinolaryngol. 2017; S18088694(17)30097-6. doi:10.1016/j.bjorl.2017.05.008. 48. Maluf G, Caldas RJ, Silva Santos PS. Use of leukocyte- and platelet-rich fibrin in the treatment of medication-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2018;76(1):88-96. doi: 10.1016/j.joms.2017.06.004 49. Özalp Ö, Yıldırımyan N, Öztürk C, Kocabalkan B, Şimşek Kaya G, Sindel A, et al. Promising results of surgical management of advanced medication related osteonecrosis of the jaws using adjunctive leukocyte and platelet rich fibrin. BMC Oral Health. 2021;21(1):613. doi: 10.1186/s12903-021-01965-7 50. Di Fede O, Canepa F, Panzarella V, Mauceri R, Del Gaizo C, Bedogni A, et al. The Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ): a systematic review with a pooled analysis of only surgery versus combined protocols. Int J Environ Res Public Health. 2021;18(16):8432. doi:10.3390/ ijerph18168432 51. Monteiro L, Vasconcelos C, Pacheco JJ, Salazar F. Photobiomodulation laser therapy in a Lenvatinib-related osteonecrosis of the jaw: a case report. J Clin Exp Dent. 2021;13(6):e626-9. doi: 10.4317/jced.58323 52. Almeida MVDC, Moura AC, Santos L, Gominho L, Cavalcanti UDNT, Romeiro K. Photodynamic therapy as an adjunct in the treatment of medication-related osteonecrosis of the jaw: a case report. J Lasers Med Sci. 2021;12:e12. doi: 10.34172/jlms.2021.12 53. Ristow O, Rückschloß T, Müller M, Berger M, Kargus S, Pautke C, et al. Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages? A long-term single-center cohort study. J Craniomaxillofac Surg. 2019;47(3)491-9. doi: 10.1016/j.jcms. 2018.12.014 54. Hayashida S, Soutome S, Yanamoto S, Fujita S, Hasegawa T, Komori T, et al. Evaluation of the Treatment Strategies for Medication-Related Osteonecrosis of the Jaws (MRONJ) and the factors affecting treatment outcome: a multicenter retrospective study with propensity score matching analysis. J Bone Miner Res. 2017;32(10):202229. doi:10.1002/jbmr.3191 55. De Lima PB, Brasil VL, De Castro JF, De Moraes Ramos-Perez FM, Alves FA, Dos Anjos Pontual ML, et al. Knowledge and attitudes of Brazilian dental students and dentists regarding bisphosphonate-related osteonecrosis of the jaw. Support Care Cancer. 2015;23(12):3421-6. doi:/10.1007/s00520-015-2689-6 75 56. R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing 2022 [Internet]. [acesso em 2023 Feb 9] Disponível em: https://www.R-project.org/ 57. Paredes L, Gonçalves LS, Miranda AMMA, Netto JNS, Perez DEC, Pires FR. Knowledge of dental professionals and Dental students on bisphosphonates and bisphosphonateassociated osteonecrosis of the jaws. Research, Society and Development. 2022;11(9):e16211931553. doi: 10.33448/rsd-v11i9.31553 58. Marliére DAA, Costa TE, Junqueira RB, Barbosa SM, Asprino L, Chaves Netto HDM. Knowledge and clinical behavior on antiresorptivemedications and osteonecrosis of the jaws: a cross-sectional study. RGO Rev Gaúch Odontol. 2019;67:e20190058. doi: http://dx.doi.org/10.1590/1981-863720190005820190018 59. Vinitzky-Brener I, Ibáñez-Mancera NG, Aguilar-Rojas AM, Álvarez-Jardón AP. Knowledge of bisphosphonate-related osteonecrosis of the Jawsamong Mexican dentists. Med Oral Patol Oral Cir Bucal. 2017;22(1):e84-7. doi: 10.4317/medoral.21433 60. Dahlgren M, Wexell CL. Uncertainty managing patients treated with antiresorptive drugs: a cross-sectional study of attitudes and self-reported behavior among dentists in Sweden. Acta Odontol Scand. 2020;78(2):109-17. doi: 10.1080/00016357.2019.1655586 61. Tanna N, Steel C, Stagnell S, Bailey E. Awareness of medication related osteonecrosis of the jaws (MRONJ) amongst general dental practitioners. Br Dent J. 2017;222(2):121-5. doi: 10.1038/sj.bdj.2017.79 62. Alqhtani NR, Almalki AK, Zuhair FA, Alenazi AA, Nabhan AB, Alqahtani M. Knowledge, Attitude, and Management of General Dentist toward Medication-related Osteonecrosis of the Jaws. J Pharm Bioallied Sci. 2020;12(Suppl 1):S151-4. doi: 10.4103/jpbs.JPBS_47_20 63. Escobedo M, García-Consuegra L, Junquera S, Olay S, Ascani G, Junquera L. Medication-related osteonecrosis of the jaw: A survey of knowledge, attitudes, and practices among dentists in the principality of Asturias (Spain). J Stomatol Oral Maxillofac Surg. 2018;119(5):395-400. doi: 10.1016/j.jormas.2018.04.008 64. Ekmekçioğlu A, Akay G, Karadağ Ö, Güngör K. The Awareness and Knowledge of Dentists about Medication-Related Osteonecrosis of Jaws. Clin Exp Health Sci. 2021;11(1):163-69. doi: 10.33808/clinexphealthsci.701257pt_BR
dc.contributor.refereesLatteshttp://lattes.cnpq.br/8389914651900629pt_BR
dc.type.degreeDoutoradopt_BR
Appears in Collections:Tese (PPGPIOS)

Files in This Item:
File Description SizeFormat 
Tese Flávia Godinho Costa Wanderley Rocha.pdfTese Flávia Godinho Costa Wanderley Rocha6,92 MBAdobe PDFView/Open
Termo De Aprovação De Defesa Pública De Tese - Flávia Godinho..pdfTermo De Aprovação De Defesa Pública De Tese - Flávia Godinho Costa Wanderley Rocha309,21 kBAdobe PDFView/Open
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.